ClinicalTrials.gg
Not yet recruitingNCT06859931Updated Mar 5, 2025

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of TQB3702 Tablets and TQB3702 Tablets+TQB3702 Placebo in Systemic Lupus Erythematosus, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 37 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
62nd of 245
120 · median 36
Started
2025
with 61 others
Phase 2
33 of 266
14 open now
Primary completion
2026-12
later than 72 of 190 live
Registered
158th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 62nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 72 of the 190 other live ones, and was the 158th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

TQB3702 is a selective kinase inhibitor. This is a Phase II clinical study aimed at evaluating the efficacy and safety of TQB3702 tablets in patients with systemic lupus erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily participate in the study and sign the ;
  • Male and female, ≥18 years old and ≤70 years old (subject to the date of signing the informed consent);
  • The diagnosis meets the classification criteria of SLE established by the International Clinical Collaboration on Lupus Research (SLICC) in 2012 and has been in place for at least 6 months (Appendix 16), excluding drug-related lupus;
  • Meet the Systemic lupus erythematosus disease activity index-2K score requirements
  • Positive for one or more of the following antibodies: positive for anti-nuclear antibodies (ANA titers greater than or equal to 1:80 by immunofluorescence) and/or positive for anti-DSDNA antibodies and/or positive for anti-Smith(anti-SM);
  • Subjects were receiving standard treatment for SLE and had received treatment for at least 3 months prior to randomization. Standard therapeutic doses of SLE were stable for at least 30 days and were stable for at least 2 weeks prior to initial administration. The standard treatment for SLE may be corticosteroids, and/or antimalarial drugs, and/or
  • At the time of screening, if the subject is taking an angiotensin-converting enzyme inhibitor or an angiotensin-II receptor blocker or a non-steroidal anti-inflammatory drug (NSAID) orally, it must be at least 2 weeks since the pre-screening dose stabilized;
  • Subjects must stop all opioids at least 1 week before the first dose;
  • Fertile subjects must consent to and commit to using a medically accepted form of throughout the study period and for at least 6 months after the final trial drug administration.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are pregnant or lactating, or who plan to have a child in the 12 months prior to the first dosing.
  • Severe lupus nephritis within 30 days prior to initial administration;
  • Central nervous system diseases caused by SLE or not caused by SLE in the 12 months before the first dose;
  • Current or past diseases other than SLE
  • There is an active and uncontrolled infection, or an infection that has recently required intravenous anti-infective therapy, or is currently being treated for any chronic infection
  • Subjects whose chest radiology within 6 months prior to screening indicates active tuberculosis
  • Have active hepatitis, or surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive + hepatitis B virus (HBV) DNA positive, or virus (HCV) RNA positive; Or a history of (HIV) infection, or a positive HIV serological result at screening; The specific antibody of Treponema pallidum was positive and the confirmatory test was positive. If HBV core antibody is positive but HBV-DNA is negative, HBV-DNA should be monitored once every 3 months.
  • Herpes or shingles infection, or a history of disseminated/complicated shingles in the 12 weeks prior to screening;
  • Cardiovascular and cerebrovascular abnormalities;
  • Have a lung disease that the investigator determines is not suitable for participation in the study
  • Subjects with a history or suspected demyelinating disease of the central nervous system;
  • Subjects with a history of or suspected demyelinating disease of the central nervous system;
  • Subjects with any type of active or with a history of malignancy;
  • Have a history of vital organ transplantation or hematopoietic stem cell/bone marrow transplantation;
  • The subject has any medical condition that may affect the absorption of oral medications (e.g., bariatric/obesity surgery, or the subject is unable to take oral medications;
  • Previous use of specific drugs;
  • Patients who underwent plasma replacement within 12 weeks prior to initial administration or treated with human immunoglobulin 4 weeks prior to initial administration;
  • Cyclophosphamide had been used within 3 months before the first dose;
  • Rituximab or any other B-cell depletion therapy within 6 months prior to initial administration;
  • Use Beliuzumab, Taitacept, tumor necrosis factor (TNF) antagonists, or other biologics before initial administration unless the elution time is met, as specified in Appendix 17;
  • Participants who have suffered a major trauma, fracture, or surgical procedure in the 4 weeks prior to screening, or who are expected to require major surgical procedures during the study period;
  • Participants who received within 28 days before the start of study treatment, inactivated vaccine within 7 days, or planned vaccination during the study period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    TQB3702 Tablets

    Administer orally on an empty stomach, once daily, for 24 consecutive weeks.

    Drug: TQB3702 Tablets

  • Experimental
    TQB3702 Tablets+TQB3702 Placebo

    Administer orally on an empty stomach, once daily, for 24 consecutive weeks. Placebo was administered orally once a day for 24 weeks.

    Drug: TQB3702 Tablets+TQB3702 Placebo

  • Placebo comparator
    TQB3702 Placebo

    Placebo was administered orally once a day for 24 weeks.

    Drug: TQB3702 Placebo

Interventions

  • TQB3702 is a selective kinase inhibitor.

  • DrugTQB3702 Tablets+TQB3702 Placebo

    TQB3702 is a selective kinase inhibitor; A placebo is a simulated drug whose physical properties, such as appearance, size, color, dosage form, weight, taste, and odor are substantially the same as the test drug, but cannot contain the active ingredients of the test drug.

  • DrugTQB3702 Placebo

    TQB3702 Placebo without drug substance.

06

What researchers measure

Primary outcomes

  1. SLE response index -4 (SRI-4)

    ≥4 point reduction from baseline in systemic lupus erythematosus disease activity index 2000 (SLEDAI-2k) score and no new the British Isles Lupus Assessment Group (BILAG) A score and no more than one new BILAG B organ domain score compared with baseline and no worsening in Physician Global Assessment (PGA) (\<0.3 points increase from baseline).

    Time frame: Baseline to week 24

Secondary outcomes

  1. SLE response index -4 (SRI-4)

    ≥4 point reduction from baseline in SLEDAI-2k score AND no new BILAG A score and no more than one new BILAG B organ domain score compared with baseline AND no worsening in PGA (\<0.3 points increase from baseline)

    Time frame: Baseline to weeks 4 and 12

  2. SLE response index -6 (SRI-6)

    ≥6 point reduction from baseline in SLEDAI-2k score AND no new BILAG A score and no more than one new BILAG B organ domain score compared with baseline AND no worsening in PGA (\<0.3 points increase from baseline)

    Time frame: Baseline to weeks 4, 12, and 24

  3. SLE Disease Activity Index -2000 score

    A tool for assessing disease activity in systemic lupus erythematosus (SLE), with a score based primarily on whether a patient develops clinical symptoms within 28 days. The higher the score, the higher the patient's disease activity.

    Time frame: Baseline to weeks 4, 12, and 24

  4. Cutaneous lupus erythematosus Area and Severity Index (CLASI score)

    A useful tool for assessing skin activity in patients with lupus erythematosus. The higher the score, the higher the patient's disease activity.

    Time frame: Baseline to weeks 4, 12, and 24

  5. Number of active (tender + swollen) joints

    Changes in the number of joints subject moves (tenderness + swelling)

    Time frame: Baseline to weeks 4, 12, and 24

  6. Medical Outcomes Study 36-Item Summary Health Survey (SF-36)

    Changes in 36 summary health surveys in the Medical Outcomes Study. The higher the score, the better the patient's self-reported quality of life.

    Time frame: Baseline to weeks 12

  7. The change of Anti double-stranded DeoxyriboNucleic Acid(ds-DNA) antibody Anti-dsdna antibody and antinuclear antibody (ANA)

    The change of anti-dsDNA antibody value and ANA value

    Time frame: Baseline to weeks 4, 12, and 24

  8. Changes in Complement 3 (C3) values and Complement 4 (C4) values

    Changes in C3 values and C4 values

    Time frame: Baseline to weeks 4, 12, and 24

  9. Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA) levels

    Changes of IgG, IgM and IgA levels.

    Time frame: Baseline to weeks 4, 12, and 24

  10. Cytokine expression levels

    Changes in cytokine expression levels

    Time frame: Baseline to weeks 4, 12, and 24

  11. Total B cell count

    Changes in total B cell count

    Time frame: Baseline to weeks 4, 12, and 24

  12. Erythrocyte sedimentation rate (ESR)

    Changes in erythrocyte sedimentation rate

    Time frame: Baseline to weeks 4, 12, and 24

  13. Frequency of adverse event (AE)

    The occurrence of all adverse medical events after the first injection.

    Time frame: From the date of signing the informed consent to 28 days after the last dosing or a new anti-tumor treatment, whichever comes first.

  14. Severity of adverse event (AE)

    The severity of all adverse medical events after the first injection.

    Time frame: From the date of signing the informed consent to 28 days after the last dosing or a new anti-tumor treatment, whichever comes first.

  15. Peak time (Tmax)

    Peak time (Tmax)

    Time frame: 1, 84, 112, 140 and 168 Days

  16. Target occupancy

    The extent to which the drug occupies the target on the cell surface

    Time frame: Day 1, 14 and 168

  17. Peak concentration (Cmax)

    Peak concentration (Cmax)

    Time frame: 1, 84, 112, 140 and 168 Days

  18. Area under the blood drug concentration time curve (AUC0-24h, AUC0-t, AUC0- ∞),

    Area under the blood drug concentration time curve (AUC0-24h, AUC0-t, AUC0- ∞),

    Time frame: 1, 84, 112, 140 and 168 Days

  19. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution (Vd/F)

    Time frame: 1, 84, 112, 140 and 168 Days

  20. Plasma clearance rate (CL/F)

    Time frame: 1, 84, 112, 140 and 168 Days

  21. Plasma elimination half-life (t1/2)

    Plasma elimination half-life (t1/2)

    Time frame: 1, 84, 112, 140 and 168 Days

  22. Steady-state peak time (Tmax, ss)

    Steady-state peak time (Tmax, ss)

    Time frame: 1, 84, 112, 140 and 168 Days

  23. Steady-state peak concentration (Cmax, ss)

    Steady-state peak concentration (Cmax, ss)

    Time frame: 1, 84, 112, 140 and 168 Days

  24. Steady-state trough concentration (Cmin, ss)

    Steady-state trough concentration (Cmin, ss)

    Time frame: 1, 84, 112, 140 and 168 Days

  25. Average steady-state blood drug concentration (Cav, ss)

    Average steady-state blood drug concentration (Cav, ss)

    Time frame: 1, 84, 112, 140 and 168 Days

  26. Area under the steady-state blood drug concentration time curve (AUCss)

    Area under the steady-state blood drug concentration time curve (AUCss)

    Time frame: 1, 84, 112, 140 and 168 Days

  27. Accumulation ratio (Rac)

    Accumulation ratio (Rac)

    Time frame: 1, 84, 112, 140 and 168 Days

  28. Volatility (DF)

    Volatility (DF)

    Time frame: 1, 84, 112, 140 and 168 Days

07

Study locations

37 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Dec 2026, 21 months later.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 47. This study's planned 21 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 5, 2025
StartEst.
Mar 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06859931
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Mar 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 5, 2025

Study contacts

Chunde Bao, Doctor
Contact
Baochunde_1678@126.com
86-21-63284622

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor TQB3702

Start the discussion